Literature DB >> 16114100

Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems.

Magdalena J Slusarz1, Artur Giełdoń, Rafał Slusarz, Jerzy Ciarkowski.   

Abstract

Vasopressin (CYFQNCPRG-NH(2), AVP) is a semicyclic endogenous peptide, which exerts a variety of biological effects in mammals. The main physiological roles of AVP are the regulation of water balance and the control of blood pressure and adrenocorticotropin hormone (ACTH) secretion, mediated via three different subtypes of vasopressin receptors: V1a, V1b and V2 receptors (V1aR, V1bR and V2R, respectively). They are the members of the class A, G-protein-coupled receptors (GPCRs). AVP also modulates several behavioral and social functions. In this study, the interactions responsible for AVP binding to vasopressin V1a and V2 receptors versus the closely related oxytocin ([I3,L8]AVP, OT) receptor (OTR) have been investigated. Three-dimensional models of the activated receptors were constructed using multiple sequence alignment, followed by homology modeling using the complex of activated rhodopsin with Gt(alpha) C-terminal peptide of transducin MII-Gt(338-350) prototype as a template. AVP was docked into the receptor-G(alpha) systems. The three lowest-energy pairs of receptor-AVP-G(alpha) (two complexes per each receptor) were selected. The 1-ns unconstrained molecular dynamics (MD) of complexes embedded into the fully hydrated 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (POPC) lipid bilayer was conducted in the AMBER 7.0 force field. Six relaxed receptor-AVP-G(alpha) models were obtained. The residues responsible for AVP binding to vasopressin receptors have been identified and a different mechanism of AVP binding to V2R than to V1aR has been proposed. Copyright (c) 2005 European Peptide Society and John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16114100     DOI: 10.1002/psc.714

Source DB:  PubMed          Journal:  J Pept Sci        ISSN: 1075-2617            Impact factor:   1.905


  10 in total

Review 1.  Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment.

Authors:  Hanne B Moeller; Søren Rittig; Robert A Fenton
Journal:  Endocr Rev       Date:  2013-01-29       Impact factor: 19.871

2.  Membrane protein stability analyses by means of protein energy profiles in case of nephrogenic diabetes insipidus.

Authors:  Florian Heinke; Dirk Labudde
Journal:  Comput Math Methods Med       Date:  2012-03-15       Impact factor: 2.238

3.  Arginine-, D-arginine-vasopressin, and their inverso analogues in micellar and liposomic models of cell membrane: CD, NMR, and molecular dynamics studies.

Authors:  Emilia A Lubecka; Emilia Sikorska; Dariusz Sobolewski; Adam Prahl; Jiřina Slaninová; Jerzy Ciarkowski
Journal:  Eur Biophys J       Date:  2015-08-20       Impact factor: 1.733

Review 4.  Vasopressin Proves Es-sense-tial: Vasopressin and the Modulation of Sensory Processing in Mammals.

Authors:  Janet K Bester-Meredith; Alexandria P Fancher; Grace E Mammarella
Journal:  Front Endocrinol (Lausanne)       Date:  2015-02-05       Impact factor: 5.555

5.  Mutations of Vasopressin Receptor 2 Including Novel L312S Have Differential Effects on Trafficking.

Authors:  Anatoly Tiulpakov; Carl W White; Rekhati S Abhayawardana; Heng B See; Audrey S Chan; Ruth M Seeber; Julian I Heng; Ivan Dedov; Nathan J Pavlos; Kevin D G Pfleger
Journal:  Mol Endocrinol       Date:  2016-06-29

Review 6.  A novel therapeutic effect of statins on nephrogenic diabetes insipidus.

Authors:  Leonilde Bonfrate; Giuseppe Procino; David Q-H Wang; Maria Svelto; Piero Portincasa
Journal:  J Cell Mol Med       Date:  2015-01-16       Impact factor: 5.310

7.  Development of a human vasopressin V1a-receptor antagonist from an evolutionary-related insect neuropeptide.

Authors:  Maria Giulia Di Giglio; Markus Muttenthaler; Kasper Harpsøe; Zita Liutkeviciute; Peter Keov; Thomas Eder; Thomas Rattei; Sarah Arrowsmith; Susan Wray; Ales Marek; Tomas Elbert; Paul F Alewood; David E Gloriam; Christian W Gruber
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

8.  Functional Rescue of a Nephrogenic Diabetes Insipidus Causing Mutation in the V2 Vasopressin Receptor by Specific Antagonist and Agonist Pharmacochaperones.

Authors:  Laura Szalai; András Sziráki; László Sándor Erdélyi; Kinga Bernadett Kovács; Miklós Tóth; András Dávid Tóth; Gábor Turu; Dominique Bonnet; Bernard Mouillac; László Hunyady; András Balla
Journal:  Front Pharmacol       Date:  2022-01-25       Impact factor: 5.810

9.  Characterization of three vasopressin receptor 2 variants: an apparent polymorphism (V266A) and two loss-of-function mutations (R181C and M311V).

Authors:  Stephen P Armstrong; Ruth M Seeber; Mohammed Akli Ayoub; Brian J Feldman; Kevin D G Pfleger
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

10.  A novel AVPR2 gene mutation of X-linked congenital nephrogenic diabetes insipidus in an Asian pedigree.

Authors:  Wei-Hong Guo; Qiang Li; Hong-Yan Wei; Hong-Yan Lu; Hui-Qi Qu; Mei Zhu
Journal:  J Int Med Res       Date:  2016-09-27       Impact factor: 1.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.